Every 10-Q that AdaptHealth Corp. (AHCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AHCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AHCO filings page.
AdaptHealth Corp. reported results for the quarter ended June 30, 2026. Net revenue from continuing operations was $740,307 (in thousands) compared with $657,100 (in thousands) a year earlier. The company recorded a net loss attributable to AdaptHealth of $133,929 (in thousands) versus net income of $14,674 (in thousands), driven largely by a non-cash goodwill impairment of $144,236 (in thousands) in the Respiratory Health and Wellness at Home reporting units.
Net income from discontinued operations related to the Diabetes Health business was $11,387 (in thousands) in the quarter. In June 2026 the board approved divestiture of this business, and on July 19, 2026 AdaptHealth agreed to sell it for $235.0 million in cash, with closing expected in the first quarter of 2027 subject to regulatory review and customary conditions. For the six months, net cash provided by operating activities was $239,024 (in thousands), while long-term debt (less current portion) was $1,879,809 (in thousands) following an April 2026 refinancing that established a new term loan and revolving credit facility.
AdaptHealth Corp. (AHCO) reported Q3 2025 results. Net revenue was $820.3 million versus $805.9 million a year ago. Operating income was $61.7 million, and net income attributable to AdaptHealth was $24.5 million, or diluted EPS of $0.16 (vs. $0.15). Segment revenue totaled $354.8 million in Sleep Health, $177.0 million in Respiratory Health, $150.1 million in Diabetes Health, and $138.4 million in Wellness at Home.
On the balance sheet, long‑term debt (less current) was $1.74 billion and cash was $80.4 million as of September 30, 2025. Year‑to‑date, operating cash flow was $418.6 million, with a $32.2 million pre‑tax gain from the sale of two businesses closed on May 1 and June 9, 2025. For the nine months, depreciation and amortization (including patient equipment) was $284.4 million. As of October 31, 2025, there were 135,424,334 common shares outstanding.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.